Trabedersen, for instance, has been studied in clinical trials for treating malignant gliomas, where it was found to reduce TGF-β2 levels and potentially improve patient outcomes by inhibiting tumor growth and reducing immunosuppression in the tumor microenvironment [131,161,162]. Here, TGFB2 is linked to neoplasm.